Document is current
Any future updates will be listed below
-
Authors
Pomeroy, Jeremy
Mallya, Usha G.
Yang, Min https://orcid.org/0000-0002-4864-6658
Huber, Caroline
Greatsinger, Alexandra
Hagopian, Ella
Haqq, Andrea M.
-
Funding
Funding for this research was provided by:
Rhythm Pharmaceuticals, Inc (Rhythm Pharmaceuticals, Inc)
- License Information
-
More Information
Article History
Received: 9 September 2024
Accepted: 23 July 2025
First Online: 22 August 2025
Declarations
:
: This study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments and was granted an exemption from a full review by the United States Pearl Institutional Review Board according to FDA 21 CFR 56.104 and 45CFR46.104(b)(2): (2) Tests, Surveys, Interviews on 07/01/2021
: Not applicable.
: UM and CH are full-time employees of Rhythm Pharmaceuticals, Inc. and have received company-awarded stocks or stock options. MY, AG, and EH are or were employees of Analysis Group, which received funding for supporting this research. JP’s institution received research support from Rhythm Pharmaceuticals as a co-investigator of clinical trials. AH is an advisory Board Member for Rhythm Pharmaceuticals, Inc., Novo Nordisk, Foundation for Prader-Willi Research USA; a grant Recipient for Weston Family Microbiome Initiative and Canadian Institutes of Health Research; and is primary investigator on clinical trials with Rhythm Pharmaceuticals, Inc., Acadia Pharmaceuticals and Eli Lilly.
